Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia

Fig. 5

ULK1 inhibition induces FLT3 degradation in FLT3-ITD AML cells. a FLT3-ITD AML cell lines (MOLM-13, MV4;11), U937 cells, and FLT3-ITD-inducible U937 cell lines (U937/FLT3-ITD #12, #15) were incubated, and cell lysates were subjected to western blotting using antibodies against FLT3-downstream molecules (FLT3, p-FLT3, STAT5, p-STAT5, p-MEK, p-ERK). α-Tubulin was used as a loading control. b MV4;11 cells were incubated with 2.5 μM of MRT 68921 for 48 h, and cell lysates were subjected to western blotting using antibodies against the FLT3-downstream molecules. α-Tubulin was used as a loading control. c Cell lysates were subjected to western blotting for FLT3 expression before and after treatment of FLT3-ITD-inducible U937 cell lines (U937/FLT3-ITD #12, #15) with the ULK1 inhibitor (MRT 68921; 1, 2.5 μM). α-Tubulin was used as a loading control. d MV4;11 cell lysates were subjected to western blotting for FLT3 expression after treatment of the cells with ULK1 inhibitor (MRT 68921; 2.5 μM), proteasome inhibitor (MG132; 10 μM), or both for 48 h

Back to article page